1.

Introduction
It has long been recognised that continuous androgen deprivation (CAD) therapy in patients with prostate cancer (PCa) can induce side effects such as decreased libido, impotence, decreased lean body mass, increased fat mass, increased insulin resistance, and osteoporosis [1] . These effects can significantly alter quality of life (QoL), especially in younger men. One alternative approach to CAD, recommended by the European Association of Urology (EAU) [2] and the National Institute of Health and Care Excellence [3] , is intermittent androgen deprivation (IAD) therapy, during which androgen deprivation therapy (ADT) is discontinued once prostate-specific antigen (PSA) levels fall below a certain level and is restarted when PSA levels begin to rise [4] . The 2015 EAU guidelines suggest that IAD can be offered to a range of patients with PCa after a standardised induction period of ADT [2] , providing they are willing and able to comply with the strict follow-up (and clinical examinations) necessitated by this treatment approach.
Although the concept of IAD is not new [5] , the literature still largely fails to answer the question of the relative benefits of IAD versus CAD, especially in nonmetastatic patients. Recent studies conclude that IAD is noninferior to CAD in terms of overall survival (OS), although one study in patients with metastatic disease showed small OS benefits with IAD [6] and was equivalent to CAD for cancer control. Findings are less clear regarding prevention of long-term effects of ADT and QoL outcomes [4, [7] [8] [9] ; however, previous studies were heterogeneous in design, study populations, and treatment schedules.
As such, the ICELAND study, conducted in 20 European countries, aimed to add to the knowledge base regarding the efficacy and safety profile of IAD compared with CAD, focusing on a nonmetastatic population treated with the luteinising hormone-releasing hormone (LHRH) analogue leuprorelin acetate 3-mo depot, which has not been widely evaluated in the context of IAD.
2.
Patients and methods
Design and procedures
This was a 42-mo phase 3b open-label randomised multicentre study, recruiting patients from 102 centres in 20 European countries (Supplementary Table 1 ). Men with locally advanced PCa (T3ÀT4) or elevated or rising PSA levels (!5 mg/ml) after radical prostatectomy (RP) or radiotherapy were screened. Inclusion criteria were age !18
and <80 yr, Gleason score !6, Eastern Cooperative Oncology Group (ECOG) performance status score 0-2, and !5-yr life expectancy.
Patients were excluded if they had any other malignancy or metastatic disease, were receiving chemotherapy or other hormonal therapy, had testosterone levels 1.7 nmol/l or 50 ng/dl, or had any condition that would preclude safe study completion. Patients underwent a rigorous assessment at screening, including TNM classification and a biopsybased Gleason assessment. Radionuclide bone scan (technetium 99m-methylene diphosphonate bone scintigraphy) or a computed tomography scan of the abdomen and pelvis was also performed to exclude the presence of metastases. Patients provided written informed consent prior to study entry. The protocol was reviewed by the independent ethics committee/institutional review board at each study centre.
Treatment
The induction treatment phase ran from screening (visit 1) to 
Primary end point
The primary end point was time to PSA progression, defined as three consecutive increasing PSA values !4 ng/ml at least 2 wk apart while receiving leuprorelin. [10, 11] were completed at visits 2-16 and at early withdrawal.
Secondary end points
Safety
Reported adverse events (AEs) were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, v.3.0.
Power calculations and statistical analyses
With 350 randomised patients per arm, it was calculated that the study would provide 90% power to demonstrate superiority on the primary end point at the final analysis (3 yr after randomisation) if the proportion of patients with PSA progression at 3 yr was 38.9% in the CAD arm, based on previous estimates [12] , and <27.3% or >51.2% in the IAD arm.
Efficacy, safety, and tolerability data were analysed for all patients who were randomised at visit 4 and treated. Time-to-event data were analysed using the Kaplan-Meier method.
Results
Of 1131 screened patients, 933 entered the induction phase ( Fig. 1 ). There were no relevant differences between treatment groups for baseline disease characteristics or comorbidities (Table 1) . During induction, median testosterone levels for all patients decreased from 397 ng/dl (13.8 nmol/l) to 11.0 ng/dl (0.4 nmol/l) at month 3, with a further small decline at month 6. Median PSA levels decreased from 8.6 ng/ml to 0.20 ng/ml at month 3 and remained at this level at month 6.
Overall, 701 patients were randomised ( Fig. 1 ), of whom 58% had locally advanced disease, 26.7% had relapsing PCa following RP, and 15.3% had relapsing PCa following other therapies. A total of 131 patients (19.1%) withdrew after randomisation: 70 in the CAD group and 61 in the IAD group. Supplementary Table 2 details the primary reasons for study withdrawal. Death, n = 6 (2.6%) Withdrawal of consent, n = 13 (5.6%) Subject lost to follow-up, n = 3 (1.3%)
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Protocol violation, n = 5 (2.2%) Worsening of disease, n = 2 (0.9%) Other, n = 22 (9.5%)
Withdrawals before follow-up (IAD) Safety, n = 45 Efficacy, n = 44
There is a discrepancy in the nonrandomised group due to a patient who was not documented as a screening failure, although he should have been, based on the fact that one of the inclusion criteria was not met (locally advanced but TNM classification was missing); no leuprolide acetate was administered. b Population additionally included patients who were not randomised. CAD = continuous androgen deprivation; IAD = intermittent androgen deprivation.
3.1.
Description of intermittent androgen deprivation cycles
The median number of IAD injections administered during the randomised phase was 3 (range: 2 ); estimated 3-yr PSA PFS percentage was 13.2 (95% CI, 10.0À17.5) and 13.1 (95% CI, 9.7À17.5) for CAD and IAD, respectively. There was a steep decrease in mean PSA levels by the end of the induction phase in both groups that was maintained through to visit 16 (Fig. 3) . Overall, 86 men died within 5 yr of study entry (44 in the CAD group and 42 in the IAD group) with no difference in OS between groups (p = 0.969) (Fig. 4) . The estimated 5-yr OS percentage was 85.0 (95% CI, 80.0À88.8) and 81.8 (95% CI, 74.7À87.2) for CAD and IAD, respectively; this difference was not statistically significant.
Most CAD patients maintained castrate levels of testosterone throughout treatment (values remained between 9.0 and 12.9 ng/dl [0.3 and 0.5 nmol/l]), with breakthrough events occurring in 22 patients (6.3%). Time to conventional testosterone breakthrough during CAD is shown in Supplementary Figure 3. 
3.4.
World Health Organization/Eastern Cooperative Oncology
Group performance status
The patients' WHO/ECOG status tended to deteriorate toward the end of the treatment period, with no notable differences between treatment groups. 
3.5.
Quality of life
QoL using EORTC QLQ-C30 was comparable for the IAD and CAD groups (Supplementary Table 3 ). For the functional scales, the mean scores were all >80 with no notable changes during the randomised phase. Mean global health status scores decreased slightly during the randomised phase, with no notable differences between groups. Nausea, vomiting, and appetite loss were the most distressing symptoms reported. Additional QoL data are reported in Supplement 1 and Supplementary  Table 4 .
[ [ 0 1 6 ) 7 2 0 -7 2 7 3.6.
( F i g . _ 3 ) T D $ F I G ]
( F i g . _ 2 ) T D $ F I G ]
E U R O P E A N U R O L O G Y 6 9 ( 2
Toxicity and adverse events
During the randomised phase, 510 patients (73.9%) had one AE or more, with no clinically relevant difference between groups (Table 2) . Overall, 178 patients (25.8%) had one or more serious AEs. The most common AEs were hot flushes, hypertension, and constipation (Table 2 ); most were grade 1 (mild) or grade 2 (moderate). Supplementary Table 5 shows the AEs occurring in !2% of patients during the randomised phase. Forty-two patients (6.1%) discontinued randomised treatment due to AEs. Analysis of AEs in patients with locally advanced versus relapsing PCa at baseline revealed no differences between CAD and IAD regarding number of AEs, serious AEs, or AEs leading to drug discontinuation. Twentyfour patients (3.5%) died during randomised treatment; no deaths were deemed related to treatment.
Discussion
In this large multicentre randomised study of IAD and CAD in patients with relapsing M0 after RP or radiotherapy or locally advanced PCa, there were no statistically significant or clinically relevant differences between groups for any timeto-event end points (time to PSA progression, PSA PFS, or OS) or mean PSA levels over time. Results were seen in the context of considerably fewer injections in the IAD than CAD group (median: 3 for IAD and 12 for CAD). However, there were no apparent differences in performance status, QoL, or treatment tolerability between groups; both treatment strategies were similarly well tolerated, and most drugrelated (and non-drug-related) AEs were mild to moderate. A number of previously published studies have compared CAD and IAD, many in samples of <500 patients [4, [6] [7] [8] [9] [12] [13] [14] [15] [16] [17] [18] [19] [20] , but only one phase 3 study has been conducted in a purely nonmetastatic population [13] . Crook et al compared IAD with CAD in a large patient group that previously received primary or salvage radiotherapy for localised PCa [13] . IAD was found to be noninferior to CAD with respect to OS (median: 8.8 vs 9.1 yr). All other studies comparing IAD with CAD included either a mix of patients with metastatic and nonmetastatic disease, or only patients with metastatic disease. Some of these have shown better QoL or improvement in individual side effects among those treated with IAD compared with CAD [14, 17] . A recent open-label study assessing IAD with a LHRH antagonist in 213 patients of varying disease stage observed improved sexual functioning and fewer AEs during the off-treatment period [21] .
Benefits of IAD on sexual functioning and AEs were also confirmed in a recent meta-analysis of 13 trials composed of 6419 patients with hormone-sensitive PCa [8] . Although these findings are generally positive, it has been suggested that such benefits are at best modest and may depend on offtreatment period length and time to recovery of testosterone levels [7] . Taken together, these studies fail to provide consistent support for the theoretical IAD benefits, although they suggest there is no disadvantage to this approach either.
In our study, PSA progression in the CAD arm was markedly lower than reported in the study by de Leval et al on which our power assumptions were based, although the small sample size and different population in that study (n = 33 in the CAD group) could at least partly explain the difference [12] .
IAD requires fewer drug doses, potentially leading to cost savings [4, 22] . Although drug administration costs are likely to be lower for IAD, it should be noted that this approach requires strict follow-up monitoring, resulting in costs not associated with CAD that would need to be balanced against any absolute cost reductions from decreased drug use.
Strengths of this study are its large sample size, multiple objective outcome measures, and the exclusively nonmetastatic disease population. Our study, which adds to the small number of well-powered comparative studies in this patient population, is the first industry-sponsored study of its kind. We recognise that the treatment approach for the patients in the ICELAND study may have been different if conducted today; however, at the time of study initiation (2006), the options presented to patients were in line with typical practice and accepted guidelines. The primary study limitations are the open-label design and absence of formal assessment of testosterone recovery. We also acknowledge that PSA progression, as used in our study, is not a recognised surrogate end point for efficacy. It is, however, a modest end point for objective response and is strongly associated with OS [23] . Furthermore, the other outcomes used in the ICELAND study, namely PFS and OS, are of major clinical interest. Taken together, these end points provide appropriate data to contribute meaningfully to the knowledge base on IAD versus CAD.
Conclusions
In this open-label trial, IAD and CAD administered after a 6-mo induction with leuprorelin acetate 22.5 mg 3-mo depot demonstrated comparable efficacy, tolerability, and QoL in patients with nonmetastatic locally advanced or relapsing PCa. The principal potential benefits of IAD compared with CAD include reduced drug acquisition costs with comparable OS rates. There were no apparent differences in QoL benefits between the treatment groups. Critical revision of the manuscript for important intellectual content:
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